Now showing items 1-5 of 5
Cardiovascular drug monitoring using quantitative LC-HRMS analysis of self-collected micro-volume blood samples
Background Evidence suggests that ˃50% of cardiovascular (CVD) disease patients do not adhere to treatment thus impacting on patient health, additional healthcare costs and medicines wastage. DBS microsampling combined ...
Quantitative LC-HRMS determination of selected cardiovascular drugs, in dried blood spots, as an indicator of adherence to medication
Dried blood spot (DBS) sampling was investigated as a means of obtaining micro-volume blood samples for the quantitative analyses of ten commonly UK prescribed cardiovascular drugs as an indicator of medication adherence. ...
Performance of two different microsamplers for the LC-HRMS analysis of 10 cardiovascular drugs
Introduction: Evidence suggests that ˃50% of heart disease patients do not adhere to treatment. This means half of the 370 million prescriptions dispensed for cardiovascular diseases (CVD) in the UK yearly, are wasted . ...
It’s in a drop of blood – or is it?
Introduction: Over 355 million prescriptions were dispensed for heart diseases in the UK in 2013. Half of these, costing the NHS £2.3 billion, were wasted because patients did not take their medicines as prescribed . ...
Comparison of VAMS and card based microsampling with LC-HRMS analysis to assess cardiovascular drug levels
Summary: An objective means of assessing medication adherence is needed to enable patients get the maximum therapeutic benefits from their medication. A bioanalytical assay using dried blood spot (DBS) and volumetric ...